Falcón González, Alejandro http://orcid.org/0000-0003-4531-5877
Cruz Jurado, Josefina
Llabrés Valenti, Elisenda
Urbano Cubero, Rocío
Álamo de la Gala, Maria Carmen
Martínez Guisado, María Antonia
Álvarez Ambite, Rocío
Rodríguez González, Carlos José
Amérigo Góngora, Marta
Rodríguez Pérez, Lourdes
López Álvarez, Pilar
Sánchez Rovira, Pedro
González Flores, Encarnación
Henao Carrasco, Fernando
Bayo Calero, Juan
Valero Arbizu, María
Quílez Cutillas, Alicia
Salvador Boffil, Javier
Rubio Pérez, Eloísa
Ruiz-Borrego, Manuel
Funding for this research was provided by:
Roche España (Scientific advisory, medical writing services)
Article History
Received: 15 November 2023
Accepted: 4 March 2024
First Online: 28 March 2024
Declarations
:
: Dr A. Falcón González has received research speaker honoraria from Roche, AstraZeneca, Daiichi, Eisai, Gilead, Seagen, Pfizer, Novartis, Pierre Fabre, Grünenthal and Lilly; and has received consultant honoraria from AstraZeneca, Pfizer, Daiichi, Seagen and Esteve. Dr J. Cruz Jurado has received speaker honoraria from Glaxo, AstraZeneca, Roche, Novartis, Pharmamar, Eisai, Lilly, Daichii Sankyo, Gilead, Seagen, MSD, Pierre Fabre, and Pfizer; has conducted consultant/advisory role at AstraZeneca, Roche, Novartis, Pharmamar, Eisai, Lilly, Glaxo, Daichii Sankyo, Gilead, Seagen, Deciphera, and Pfizer; and has received travel support from Novartis, Gilead, Pharmamar, and Daichii-Sankyo. Dr E. Llabrés Valentí has received research speaker honoraria from Bristol, Ipsen, AstraZeneca, Daichii, Pfizer, Gilead, Novartis and Lilly; and has received consultant honoraria from AstraZeneca, Daichii and Seagen. Dr R. Urbano Cubero has received research speaker honoraria from Pfizer, Novartis, Pierre Fabre, and Lilly. Dr MC. Álamo de la Gala has received research speaker honoraria from Roche, Pfizer, Novartis, Pierre Fabre, Bristol-Myers Squibb. Dr MA. Martinez Guisado has received research speaker honoraria from Roche, Daiichi, Gilead, Seagen, Pfizer, Novartis, Pierre Fabre, and Lilly; and has received consultant honoraria from Pfizer and Daiichi. Dr CJ. Rodríguez González has received research speaker honoraria from AstraZeneca, Eisai, MSD, GSK, Pfizer, Novartis and Lilly. Dr M. Amérigo Góngora has received funding for speaker bureau from Kyowa Kirin and Grünenthal. Dr P. López Álvarez has received research speaker honoraria from Roche, AstraZeneca, Daichii, Eisai, Pfizer, Novartis, Pierre Fabre, Amgen, Celgene and Lilly; and has received consultant honoraria from AstraZeneca, Daichii, Roche, Novartis, Celgene and Pfizer. Dr P. Sánchez Rovira has received research speaker honoraria from Roche, AstraZeneca, Pierre-Fabre Gilead, Seagen, Pfizer, Novartis, and Lilly; has received consultant honoraria from AstraZeneca, Roche, Pfizer, Novartis, and Seagen; and has received research funds from Roche and AstraZeneca. Dr E. González Flores has received research speaker honoraria from Roche, Daiichi, Gilead, Seagen, Pfizer, Novartis, and Lilly; and has received consultant honoraria from AstraZeneca, Pfizer, Novartis, Daiichi and Seagen. Dr F. Henao Carrasco has received research speaker honoraria from Roche, Daiichi, Gilead, Pfizer, Novartis, Eisai and Lilly; and has received consultant honoraria from AstraZeneca, Pfizer, Novartis, Lilly, Pierre Fabre, Daiichi and Seagen. Dr M. Valero Arbizu has received speaker grants from Pfizer, Novartis, Roche, MSD, Seagen, Pierre Fabre, Eisai, and Sanofi-Aventis; and has received research fund from Quironsalud. Dr A. Quílez Cutillas has received research speaker honoraria from Roche, AstraZeneca, Bristol, Pfizer, Novartis, Pierre Fabre, Clovis and Grunenthal; and has received consultant honoraria from GSK, Pharmamar and Clovis. Dr J. Salvador Boffil has received research speaker honoraria from Roche, AstraZeneca, Daiichi, Gilead, Pfizer, Novartis, and Lilly; and has received consultant honoraria from Pfizer, Daiichi, Roche, and Novartis. Dr M. Ruiz-Borrego has received speaker grants from AstraZeneca, Daiichi, Novartis, Pfizer, Gilead, Pierre Fabre; has received the advisory board honoraria from AstraZeneca, Daiichi, Pierre Fabre, Gilead; has received research funding from Pfizer; and has received travel support from Novartis, Roche, and Pfizer. The rest of authors declare that they have no conflict of interest.
: This study was approved by the Ethics Committee of the Hospital Universitario Virgen Macarena (Seville, Spain). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice (GCP), and in compliance with European and local requirements. Written informed consent was not required in accordance with the national legislation (Real Decreto 957/2020).
: Not applicable as this manuscript does not contain any individual personal data.